Subscribe to Press Releases

X
Subscribe

Immunotherapies for Life

Cancer vaccines

Y-mAbs is developing a vaccine strategy to prevent cancer from recurring once disease is in complete remission or in a minimal residual disease state after naxitamab or Bispecific Antibody treatment. The GD2-GD2 Vaccine in combination with the polysaccharide adjuvant Glucan, can induce a patient’s own immune system to create antibodies against tumor antigen GD2 to prevent tumor recurrence.